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The influence of a KDT501, a novel 
isohumulone, on adipocyte Function 
in Humans
Brian S. Finlin1, Beibei Zhu1, Bernard P. Kok2, Cristina Godio2, Philip M. Westgate3,  
Neile Grayson4, Robert Sims4, Jeffrey S. Bland4, Enrique Saez2 and Philip A. Kern1*
1 The Department of Internal Medicine, Division of Endocrinology, The Barnstable Brown Diabetes and Obesity Center, 
University of Kentucky, Lexington, KY, United States, 2 Department of Molecular Medicine, Scripps Research Institute,  
La Jolla, CA, United States, 3 College of Public Health, University of Kentucky, Lexington, KY, United States,  
4 Kindex Pharmaceuticals, Seattle, WA, United States
Objective: In a phase II clinical trial in nine obese, insulin-resistant humans, we observed 
that treatment with KDT501, a novel isohumulone drug, increased total and high-mo-
lecular weight (HMW) adiponectin in plasma. The objective was to determine whether 
KDT501 increased adiponectin secretion from subcutaneous white adipose tissue (SC 
WAT) and the underlying mechanism(s).
Methods: Nine obese participants with either prediabetes or with normal glucose 
tolerance plus three features of metabolic syndrome were part of the study. SC WAT 
biopsies were performed before and after 28 days of KDT501 treatment in a clinical 
research setting. In addition, a cold stimulus was used to induce thermogenic gene 
expression. Adiponectin secretion was measured, and gene expression of 130 genes 
involved in adipose tissue function was determined. The effect of KDT501 on adipocyte 
mitochondrial function was analyzed in vitro.
results: SC WAT explants secreted more total and HMW adiponectin after KDT501 
treatment (P  <  0.05). After KDT501 treatment, a number of genes involved in ther-
mogenesis and lipolysis were induced by cold (P  <  0.05). KDT501 also potentiated 
β-adrenergic signaling (P < 0.001) and enhanced mitochondrial function in adipocytes 
(P < 0.001).
Conclusion: KDT501 induced adiponectin secretion posttranscriptionally and increased 
gene expression of thermogenic and lipolytic genes in response to cold stimulation. 
These beneficial effects on SC WAT may be explained by the ability of KDT501 to poten-
tiate β-adrenergic signaling and enhance mitochondrial function in adipocytes.
Clinical Trial registration: https://www.ClinicalTrials.gov, ID number: NCT02444910.
Keywords: adiponectin, adipocyte secretion, adipose tissue biology, gene expression profiling, metabolic 
syndrome, mitochondria
inTrODUCTiOn
KDT501 is a compound chemically derived from hops that has antidiabetic effects in rodents (1). 
More specifically, KDT501 is the potassium salt of the n-(isobutyl) congener of a tetrahydro iso-alpha 
acid, also known as isohumulone. We have recently analyzed the effect of 1 month of KDT501 treat-
ment in nine obese, insulin-resistant subjects in an open-label, phase II clinical trial (2). Although 
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oral glucose tolerance did not improve significantly, there were 
improvements in several secondary outcomes. KDT501 treat-
ment reduced plasma triglyceride levels during a lipid tolerance 
test. Total and high-molecular weight (HMW) adiponectin 
were higher in plasma after KDT501 treatment (2). Adiponectin 
is an anti-inflammatory, insulin-sensitizing adipokine that is 
negatively correlated with several aspects of metabolic syndrome 
and polycystic ovary syndrome (PCOS) (3) and acts at multiple 
tissues to promote metabolic homeostasis [recently reviewed 
in Ref. (4)]. Consistent with this, plasma TNFα was reduced by 
KDT501 treatment (2).
Adiponectin is specifically expressed by adipocytes, suggest-
ing that KDT501 treatment in this clinical trial affected adipose 
tissue to increase plasma adiponectin levels (2). KDT501 has 
pleiotropic effects on gene expression in  vitro. For instance, 
KDT501 promoted adiponectin gene expression in a human 
adipocyte primary cell culture model (1). KDT501 also inhibited 
inflammatory gene expression in macrophages in  vitro (1). 
In obesity, adipose tissue secretes TNFα (5, 6), an inflammatory 
cytokine that is inversely coordinated with adiponectin expres-
sion and insulin sensitivity (7). These observations suggest 
that KDT501 treatment reduces some measures of adipose 
dysfunction in part by remodeling gene transcription.
In this study, we focused on adipose tissue to identify mecha-
nisms by which KDT501 functions in vivo in these nine obese 
human research participants. We evaluated adiponectin secretion 
from abdominal subcutaneous white adipose tissue (SC WAT) 
explant secretions of the participants before and after treatment 
with KDT501 from our phase 2 study (2). We then comprehen-
sively evaluated the subcutaneous adipose tissue transcriptional 
response to KDT501. Since KDT501 promotes weight loss in 
rodents (1), we hypothesized that KDT501 treatment would 
reduce adipose dysfunction that occurs with obesity in humans. 
Comprehensive analysis of gene expression could thus provide 
insight into the mechanism by which KDT501 increases adi-
ponectin secretion in vivo and affects overall SC WAT function. 
The panel of genes in our multiplex assay included genes involved 
in the function of adipose tissue and genes involved in adipose 
dysfunction such as inflammatory cytokines, immune cell type 
markers, and fibrosis genes. Because KDT501 was found to 
stimulate thermogenic genes in cultured human adipocytes (1), 
we measured these genes before and after a brief cold stimulus. To 
gain mechanistic insight into the effect of KDT501 on adipocytes, 
we evaluated the effect of KDT501 on adipocyte mitochondrial 
bioenergetics and fatty acid oxidation in vitro.
MaTErialS anD METHODS
Human Subjects and Study Design
All subjects gave informed consent, and the protocols were 
approved by the Institutional Review Board at the University of 
Kentucky. Recruitment for this study was through local advertis-
ing and initial phone screening eliminated from consideration 
participants who could not participate or who did not meet 
inclusion criteria, such as BMI and age. 15 potential subjects 
were invited for in-person screening, which included an OGTT 
and fasting labs, and 9 of these subjects met inclusion/exclusion 
criteria and were enrolled in the study. All nine of these sub-
jects completed the study. The characteristics of these subjects; 
inclusion and exclusion criteria; and the Phase II KDT501 
drug trial (ClinicalTrials.gov ID number NCT02444910) have 
recently been reported (2). In brief, nine obese, non-diabetic, 
insulin-resistant subjects were given KDT501 in escalating doses 
for 28 days during the summer. The relatively short duration of 
treatment and the limited doses of KDT501 was a requirement of 
the FDA during this phase 2A study. This short-term treatment 
did not cause a change in appetite, weight (pre: 100.8 ± 5.5 kg; 
post: 100.3  ±  5.7  kg; P  =  0.63), % body fat (pre: 47.5  ±  1.55; 
post: 47.6  ±  1.5; P  =  0.5), resting energy expenditure (pre: 
1,725 ± 79 kcal/day; post: 1,670 ± 106 kcal/day; P = 0.29), or res-
piratory quotient (pre: 0.86 ± 0.02; post: 0.87 ± 0.02; P = 0.0.86); 
all values are mean ± SEM. SC WAT biopsies were performed 
before and after 28 days of KDT501 treatment; all posttreatment 
biopsies were obtained between 0 and 3 days after the last dose 
of KDT501. In addition, a cold stimulus was used to determine 
whether KDT501 affected thermogenic gene induction. A sub-
cutaneous adipose biopsy was performed on the right side of 
the abdomen. An ice pack was applied to the left side of the abdo-
men for 30 min, and a second biopsy was performed 4 h later 
on the cold-stimulated adipose. A portion of the adipose tissue 
was analyzed for secretion as described below. The remaining 
adipose tissue was immediately frozen in liquid nitrogen and 
stored at −80°C.
adipose Tissue Explant Secretions
We weighed 0.5  g of fat from each SC WAT biopsy, placed 
the explant into 2  mL Dulbecco’s modified Eagles’ medium 
(DMEM), and incubated for 1 h at 37°C. The adipose explant 
was removed, and the DMEM was centrifuged to remove 
debris. The experiment thus maintained the SC WAT weight 
to volume of DMEM ratio similar to the normalization applied 
by Kovacova and colleagues (8). The medium was diluted 1:100 
and analyzed with a total and HMW adiponectin ELISA kit 
(47-ADPHU-E01; Alpco, Salem, NH, USA) according to the 
manufacturer’s instructions.
Gene Expression
RNA was prepared from the subcutaneous adipose tissue using 
a Qiagen RNAeasy Lipid Tissue Mini kit (Qiagen, Valencia, CA, 
USA). RNA quantity and quality were determined using an 
Agilent 2100 Bioanalyzer (Palo Alto, CA, USA). The expression 
of 130 genes was analyzed using the Nanostring nCounter mul-
tiplex system (gene names and accession numbers are in Table 
S1 in Supplementary Material). The data were normalized to the 
positive controls and the geometric mean of six housekeeping 
genes (Table S1 in Supplementary Material) according to the 
manufacturer’s instructions. The background level of the stand-
ard negative controls supplied by Nanostring was very low and 
not subtracted. We also determined the negative control value of 
the individual probes by doing no RNA (water) controls. These 
values, which are the average of three controls, were also low (see 
Tables S2–S5 in Supplementary Material). The gene expression 
of ERp44, ERo1-La, and DsbA-L was determined by real-time 
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reverse transcriptase polymerase chain reaction (RT-PCR) as 
described (9) and normalized the geometric mean of the same six 
genes utilized in the Nanostring assay (Table S1 in Sup plementary 
Material).
Cell Culture
Primary brown preadipocytes were isolated from neonatal 
wild-type C57BL/6 pups as previously described (10). Briefly, 
brown adipose tissue was digested for 30  min at 37°C using 
1.5 mg/mL collagenase type I (Worthington) in PBS containing 
the following additional components: 62  mM NaCl, 2.5  mM 
KCl, 0.65  mM CaCl2, 2.5  mM glucose, 50  mM HEPES, and 
2% fatty acid-free BSA. Cells were strained using a 100  µM 
filter, plated, and grown to confluence in 20% FBS-DMEM. 
Differentiation was initiated by replacing the growth media 
with 10% FBS-DMEM supplemented with 172  nM insulin, 
1  µM dexamethasone, 0.5  mM 3-isobutyl-1-methylxanthine 
(IBMX), 1 nM triiodothyronine (T3), and 1 µM rosiglitazone. 
After 2 days, adipogenesis induction media were replaced with 
10% FBS-DMEM containing 172 nM insulin and 1 nM T3 and 
refreshed every other day. Five days after the induction of differ-
entiation, differentiated brown adipocytes were replated onto a 
96-well Seahorse plate at a density of 5,000 cell/well and allowed 
to settle overnight. Cells were treated with vehicle, rosiglita-
zone, and KDT501 for 16  h before analysis of mitochondrial 
respiration parameters on a Seahorse XFe96 extracellular flux 
analyzer. 3T3-L1 preadipocytes were cultured and differenti-
ated as previously described (11). Briefly, 3T3-L1 preadipocytes 
were maintained in 10% BCS-DMEM. To induce differentia-
tion, cells were replated and allowed to reach confluence. Two 
days post-confluence, cells were treated with 172 nM insulin, 
1 µM dexamethasone, 0.5 mM IBMX, and 1 µM rosiglitazone 
in 10% FBS-DMEM. After 2  days, adipogenesis induction 
media were replaced with 10% FBS-DMEM supplemented with 
172  nM insulin. Differentiated adipocytes were replated onto 
96-well Seahorse plates at 6,000 cells per well and allowed to 
settle overnight. Cells were treated with vehicle, rosiglitazone, 
or KDT501 for 48  h before the fatty acid oxidation rate was 
measured in the Seahorse XFe96.
Mitochondrial Bioenergetics and Fatty 
acid Oxidation rate assays
Analyses of mitochondrial respiration parameters and fatty acid 
oxidation rates were performed in an XFe6 instrument following 
the manufacturer’s instructions (Seahorse Bioscience). Briefly, 
primary brown adipocytes were switched to substrate-free 
DMEM supplemented with 10 mM glucose, 10 mM pyruvate, 
1× Glutamax, 10 mM HEPES pH 7.4, and a Mitostress test was 
performed. The oxygen consumption rate was measured in real 
time to document basal respiration and four sequential injections 
were then performed: (1) 100 nM norepinephrine (NE); (2) 2 µM 
oligomycin; (3) 1  µM carbonyl cyanide-4-(trifluoromethoxy)
phenylhydrazone (FCCP); and (4) a combination of 2 µM rote-
none and 2 µM antimycin A. To measure the fatty acid oxidation 
rate, 3T3-L1 adipocytes were switched to assay media (Krebs–
Henseleit Buffer, 2.5 mM final glucose, 0.5 mM carnitine, and 
5  mM HEPES; pH 7.4) for 1  h before the addition of vehicle 
(33 µM BSA) or 167 µM palmitate in complex with BSA (5:1). 
Real-time oxygen consumption was measured immediately after 
palmitate addition and following injections of 4 µM oligomycin, 
4  µM FCCP, and a combination of 2  µM rotenone and 2  µM 
antimycin A. The concentration of oligomycin and FCCP was 
increased in fatty acid oxidation rate assays to account for the 
presence of BSA.
Statistics
Unless noted, data were analyzed with a two-tailed, paired t-test. 
To identify genes that had a differential response to cold stimu-
lus by KDT501 treatment, we calculated the difference in the 
response to cold stimulus before and after KDT501 treatment 
and then performed a two-sample t-test on this difference. 
Statistical significance was set at P  <  0.05. Data from in  vitro 
expe riments with cultured adipocytes were analyzed by one-way 
analysis of variance (ANOVA).
rESUlTS
KDT501 Treatment Stimulates  
adiponectin Secretion
We previously reported that KDT501 treatment increased total 
and HMW adiponectin levels in plasma (2). When the SC WAT 
biopsies were performed in that study, a portion was immedi-
ately frozen for mRNA analyses and another portion (0.5  g) 
was placed in DMEM for 1 h so that we could analyze secreted 
proteins. We evaluated total and HMW adiponectin secretion 
from SC WAT explants before and after KDT501 treatment. 
KDT501 treatment induced a 1.5-fold increase in the secretion of 
total adiponectin (Figure 1A; P < 0.05) and HMW adiponectin 
(Figure 1B; P < 0.05) from the adipose tissue explants. However, 
adiponectin gene expression was unchanged by KDT501 treat-
ment (Figure 1C), indicating that the increase in secretion occurs 
by a posttranscriptional mechanism. These results indicate that 
increased secretion of adiponectin from subcutaneous adipose 
tissue contributes to the increase in plasma adiponectin of these 
research participants after KDT501 treatment (2). Linear regres-
sion modeling was used to assess associations between changes 
in adiponectin secretion by KDT501 treatment and gender, age, 
and BMI. However, results were not statistically significant and 
therefore are not presented.
Effect of KDT501 on adipose  
Tissue Gene Expression
To identify potential mechanisms of action of KDT501, we 
analyzed gene expression in abdominal SC WAT with the 
Nanostring nCounter multiplex system. The gene panel com-
prised cytokines, chemotactic factors, immune cell markers, 
fibrosis markers, angiogenesis markers, genes involved in lipid 
handling, adipogenesis makers, genes involved in thermo-
genesis, and markers of brown and beige adipose (Table S1 in 
Supplementary Material). Table 1 shows that KDT501 treatment 
caused significant changes in only four adipose genes; four 
additional genes with non-significant trends (0.05 < P < 0.1) for 
FiGUrE 1 | KDT501 induces total and high-molecular weight (HMW) 
adiponectin secretion by adipose tissue explants from obese, insulin-resistant 
subjects. Adipose tissue explants obtained before and after KDT501 
treatment were incubated in Dulbecco’s modified Eagles’ medium (DMEM) 
for 1 h at 37°C. (a) Total and (B) HMW adiponectin concentrations in the 
DMEM were measured by ELISA and are expressed as the concentration/g 
adipose/h. (C) Adiponectin gene expression was measured in the 
corresponding adipose tissue biopsy with the Nanostring nCounter system 
as described in the Section “Materials and Methods.” Data represent the 
mean ± SEM (n = 9); data in all panels were analyzed by a paired, two-tailed 
Student’s t-test (*P < 0.05).
TaBlE 1 | Gene expression changed by KDT501 treatment.
Genea Pre KDT501 Post KDT501 Fold change P
Post/pre
TNFRSF12A 12 ± 2 16 ± 2 1.345 0.037
ACACA 229 ± 45 196 ± 35 0.857 0.038
MPZL2 52 ± 8 73 ± 12 1.407 0.041
DGAT2 12,059 ± 2,187 10,482 ± 1,941 0.869 0.043
LPL 17,455 ± 2,836 15,793 ± 2,584 0.905 0.068
TMEM26 16 ± 2 13 ± 2 0.856 0.072
TIMP1 1,382 ± 89 1,600 ± 158 1.157 0.075
DIO2 27 ± 6 38 ± 9 1.392 0.095
aSCWAT was isolated before and after KDT501 treatment, and gene expression 
determined with the Nanostring nCounter system as described in the Section 
“Materials and Methods.”
The data are presented as means (nCounter Counts) ± SEM (n = 9; two-tailed, paired 
Student’s t-test).
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change are also indicated in Table 1. KDT501 treatment reduced 
the mRNA expression of ACACA (Table 1; 0.86-fold; P = 0.038), 
which regulates fatty acid synthesis, and DGAT, which regulates 
triglyceride formation (Table 1; 0.87-fold; P = 0.043). The mRNA 
expression of LPL, which regulates lipid and lipoprotein uptake, 
tended to be reduced (Table 1; P = 0.068). Together, these results 
suggest a slight reduction in genes controlling adipose tissue 
lipid synthesis, uptake, and storage. MPZL2, which is a brown 
adipose marker (12), was induced 1.4-fold (Table 1; P = 0.041), 
and there was a trend for an increase in DIO2, which is involved 
in energy metabolism through the conversion of T4 into T3. 
However, UCP1 (P = 0.7) and PGC1α (P = 0.37), genes that are 
characteristic of brown and beige adipocytes, were not changed 
(Table S2 in Supplementary Material). The significance of the 
increases in MPZL2 and TNFRSF12A (Fn14, which is involved 
in many cell processes, especially involving tissue injury) is 
not known. Although KDT501 has anti-inflammatory effects 
in vitro, KDT501 treatment did not significantly reduce TNFα, 
IL12β, IL1β, or other inflammatory cytokines and immune cell 
markers in the multiplex assay panel (Table S2 in Supplementary 
Material). Finally, KDT501 did not change leptin gene expression 
(Table S2 in Supplementary Material). The data for all of the genes 
measured and the negative control values for each probe are in 
Table S2 in Supplementary Material.
KDT501 Treatment alters the response  
of adipose Tissue to Cold Stimulation
KDT501 promotes weight loss in mice, and microarray results 
from human adipocytes indicate that KDT501 stimulates ther-
mogenic pathways in adipocytes (1), suggesting that KDT501 
may promote WAT beiging. We have previously reported that a 
30-min cold exposure stimulates beiging pathways in the adipose 
tissue of lean humans (13). Therefore, before and after KDT501 
treatment, we applied an ice pack to one side of the abdomen 
for 30  min and 4  h later performed an adipose tissue biopsy, 
as described in the Section “Materials and Methods.” We then 
determined whether this cold stimulus changed gene expression 
and whether KDT501 treatment altered the response to cold. 
Before KDT501 treatment, the application of cold resulted in 
TaBlE 3 | Gene expression changed by cold after KDT501 treatment.
Genea Pre cold Post cold Fold change P
Post/pre
ANGPTL4 1,136 ± 174 1,659 ± 163 1.46 0.001
CCL1 7 ± 1 12 ± 1 1.59 0.003
BCL2 456 ± 35 543 ± 45 1.19 0.004
CSF2 46 ± 4 53 ± 3 1.17 0.009
LIPE 225 ± 27 245 ± 26 1.09 0.018
CEBPA 6,498 ± 568 7,549 ± 504 1.16 0.019
PPARA 179 ± 13 192 ± 12 1.07 0.030
VEGFA 1,013 ± 86 1,150 ± 75 1.13 0.035
PPARGC1A 48 ± 6 57 ± 9 1.19 0.038
DIO2 41 ± 9 24 ± 5 0.58 0.049
TEK 263 ± 18 305 ± 24 1.16 0.051
MMP9 311 ± 117 210 ± 42 0.68 0.052
ABHD5 537 ± 65 597 ± 74 1.11 0.054
FABP3 219 ± 61 148 ± 13 0.68 0.065
ITGAM 291 ± 27 256 ± 19 0.88 0.068
ANGPTL1 288 ± 27 222 ± 14 0.77 0.075
PNPLA2 6,664 ± 648 7,129 ± 490 1.07 0.078
LPL 16,496 ± 2,584 18,240 ± 2,305 1.11 0.090
FGF2 1,019 ± 107 120 ± 91 1.10 0.092
aSCWAT was isolated before and after the cold stimulus after KDT501 treatment,  
and gene expression was determined with the Nanostring nCounter system as 
described in the Section “Materials and Methods.”
The data are presented as means (nCounter Counts) ± SEM (n = 9; two-tailed,  
paired Student’s t-test).
TaBlE 2 | Gene expression changed by cold before KDT501 treatment.
Genea Pre cold Post cold Fold change P
Post/pre
SCD 49,210 ± 12,496 44,454 ± 12,115 0.90 0.008
AGTR2 7 ± 1 4 ± 1 0.66 0.013
MMP14 548 ± 40 499 ± 34 0.91 0.030
IL18 88 ± 10 74 ± 5 0.83 0.034
FABP1 10 ± 2 5 ± 1 0.51 0.055
ACLY 2,998 ± 624 2,490 ± 444 0.83 0.061
ADRB2 72 ± 4 66 ± 4 0.92 0.066
CD163 1,074 ± 84 978 ± 71 0.91 0.069
THBS1 968 ± 125 1,163 ± 149 1.20 0.079
RBP4 23,669 ± 1,752 21,269 ± 2,232 0.90 0.091
CCL24 90 ± 21 75 ± 16 0.83 0.094
ADIPOQ 22,520 ± 1,671 20,773 ± 1,250 0.92 0.100
aSCWAT was isolated before and after the cold stimulus before KDT501 treatment,  
and gene expression determined with the Nanostring nCounter system as described  
in the Section “Materials and Methods.”
The data are presented as means (nCounter Counts) ± SEM (n = 9; two-tailed,  
paired Student’s t-test).
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the significant repression of four unrelated genes, SCD, MMP14, 
AGTR2, and IL18 (Table 2; data for all of the remaining genes 
are in Table S3 in Supplementary Material).
After KDT501 treatment, a number of genes involved in 
lipolysis and lipid catabolism were significantly induced by cold 
(Table 3). These included PPARα, PGC1α, HSL, and ANGPTL4 
(Table 3). Adipose triglyceride lipase (PNPLA2) and the coacti-
vator of ATGL (CGI-58; ABHD5) showed a trend for induction 
(Table  3). VEGF, which stimulates angiogenesis and beiging 
(14), was also induced by icing (Table 3). Despite the induction 
of lipolytic genes and PGC1α by cold, the 1.2-fold increase in 
UCP1 was not significant (P = 0.34; Table S4 in Supplementary 
Material). CCL1, a chemokine for eosinophils and Th2 T  cells 
(15, 16), was induced by cold after KDT501, which could be 
important given the role of type 2 immunity (e.g., IL4 and IL-13) 
in adipose beiging (17–20). Data for the remaining genes are in 
Table S4 in Supplementary Material.
We identified genes that had a differential response to cold 
before and after KDT501 treatment as described in methods 
(Table S5 in Supplementary Material). This analysis identified 
many of the same genes in Table 3 and some additional genes, 
providing further insight. Before KDT501 treatment, the gene 
expression of the thermogenic genes PGC1α, TMEM26, and 
PPARα decreased slightly after cold stimulation; after KDT501 
treatment, the expression of these genes increased (Figures 2A–C; 
P < 0.05). VEGF, which induces beiging (14) and angiogenesis, 
was also increased by cold after KDT501 treatment (Figure 2D; 
P < 0.01). PAI-1 is regulated by TGFβ signaling, which inhibits 
PGC1α and energy expenditure (21); PAI-1 was increased by cold 
before KDT501, but did not increase after KDT 501 (Figure 2E; 
P  <  0.05). Overall, this suggests that KDT501 promotes the 
expression of genes involved in lipolysis and fat catabolism in 
response to cold. In addition, LPL increased in response to cold 
after KDT501 treatment (Figure 2F).
KDT501 Enhances β-adrenergic 
responses and Fatty acid Oxidation  
in adipocytes
A potential explanation for the observation that KDT501 treat-
ment enhances expression of thermogenic genes in response 
to cold is that KDT501 sensitizes adipocytes to β-adrenergic 
stimuli. To directly test this notion, fully differentiated mouse 
primary brown adipocytes were pretreated with KDT501 or 
rosiglitazone for 16 h, and their response to acute exposure to 
NE was then monitored in real time by measuring the rate of 
oxygen consumption in a Seahorse XFe instrument. As expected 
for brown adipocytes, NE exposure stimulated oxygen consump-
tion in vehicle (DMSO)-treated cells (Figure 3A). Pretreatment 
with KDT501 robustly enhanced the response to NE (Figure 3A; 
KDT501 P < 0.001; rosiglitazone P < 0.001). Pretreatment with 
the positive control rosiglitazone had a similar effect. To expand 
these observations and determine the extent to which KDT501 
treatment could also induce a more oxidative state in white adi-
pocytes, we treated fully differentiated 3T3-L1 adipocytes with 
KDT501 for 48 h and determined the rate of fatty acid oxidation. 
KDT501 treatment significantly increased the endogenous, or 
basal (P < 0.001), and the maximal (P < 0.001) rate of exogenous 
fatty acid oxidation (Figure 3B), suggesting that KDT501 treat-
ment boosts mitochondrial function. Together, these data show 
that KDT501 has direct effects on adipocytes, potentiating 
β-adrenergic signaling and fatty acid oxidation.
Cold Treatment Stimulates adiponectin 
Secretion
The analysis of gene expression and in vitro assays above suggest 
that KDT501 enhances β-adrenergic responses of adipocytes. 
FiGUrE 2 | KDT501 treatment alters the subcutaneous white adipose tissue (SC WAT) transcriptional response to cold exposure. The Nanostring nCounter system 
was used to measure gene expression in SC WAT of subjects treated before and after 1 month KDT501 treatment. a-F) Genes that had a different response to the 
cold stimulus were identified as described in the Section “Materials and Methods.” Data represent the mean ± SEM (n = 9); data in all panels were analyzed by a 
paired, two tailed Student’s t-test of the change in gene expression by cold before and after KDT501 treatment (*P < 0.05; **P < 0.01).
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Recently, a study by Komai and colleagues found that β- adren-
ergic signaling promotes adiponectin secretion (22). Since cold 
stimulates the sympathetic nervous system and β-adrenergic 
signaling, another potential mechanism for KDT501 stimulation 
of adiponectin secretion could involve this pathway. To explore 
this further, we measured adiponectin protein levels from the SC 
WAT explants and observed that cold-stimulated adiponectin 
secretion. Cold-stimulated total (Figure 4A; P < 0.01) and HMW 
adiponectin (Figure 4B; P < 0.01) secretion from the SC WAT 
explants before KDT501 treatment but did not affect adiponec-
tin mRNA expression (Figure  4C). Cold also stimulated total 
(Figure 4D; P < 0.05) and HMW adiponectin (Figure 4E; P < 0.01) 
secretion from the SC WAT explants after KDT501 treatment but 
did not affect adiponectin mRNA expression (Figure 4F).
Three proteins that promote adiponectin secretion have been 
identified and could thus act posttranscriptionally to increase 
FiGUrE 3 | Adipocytes treated with KDT501 show a magnified response  
to norepinephrine and increased fatty acid oxidation rate. (a) Mouse primary 
brown adipocytes were treated for 16 h with DMSO (vehicle), KDT501 
(10 µM), or rosiglitazone (2 µM). Oxygen consumption rate was measured  
on a Seahorse XFe96 as described in the Section “Materials and Methods.” 
(B) 3T3-L1 adipocytes were treated for 48 h with KDT501 (10 µM) or 
rosiglitazone (2 µM), and the rate of basal (endogenous) and maximal 
(exogenous palmitate added) fatty acid oxidation measured in real time  
using the XFe96. Data represent four biological replicates. Error bars  
indicate SD. **P < 0.01; ***P < 0.001 by one-way analysis of variance.
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adiponectin secretion. Because of the increase in adiponectin 
secretion without any change in mRNA level, we therefore 
determined whether KDT501 or cold affected the expression of 
these by real-time RT-PCR (primer sequences are in Table  4). 
KDT501 treatment alone did not affect the mRNA expression of 
any of these; however, all three were induced by cold. ERp44 was 
induced by cold (Figure 5A; pre: P < 0.05; post: P < 0.001), and 
KDT501 enhanced this effect (Figure 5A; P < 0.05). Ero-La was 
induced by cold after KDT501 (Figure 5B; P < 0.05). DsbA-L was 
induced by cold before and after KDT501 treatment (Figure 5C; 
pre: P < 0.05; post: P < 0.01).
Summary
In summary, KDT501 treatment had a beneficial effect on SC 
WAT of obese human research participants. KDT501 increased 
adiponectin secretion by a posttranscriptional mechanism and 
altered the transcriptional response of human adipose tissue 
to cold stimulation, inducing the expression of many genes 
involved in thermogenesis and lipolysis. Consistent with these 
obser vations, the ability of KDT501 to enhance the response of 
cultured adipocytes to β-adrenergic stimuli and increase mito-
chondrial function provides a potential mechanism of action.
DiSCUSSiOn
There is a need to develop new therapies to combat obesity 
and obesity-related disorders such as metabolic syndrome, 
non-alcoholic fatty liver disease and steatohepatitis, and the 
lipodystrophy of PCOS. We previously reported that KDT501 
treatment of obese, insulin-resistant subjects for 28 days resulted 
in an increase in plasma adiponectin and HMW adiponectin (2). 
In this study, we found that SC WAT from these obese, non- 
diabetic human subjects is a target of KDT501 treatment and 
investigated the mechanistic basis of its action. KDT501 stimu-
lates total and HMW adiponectin protein secretion from SC 
WAT explants, and this may be related to the ability of KDT501 
to enhance mitochondrial function, which was revealed in 
experiments using cultured adipocytes. Furthermore, addi-
tional analysis uncovered additional effects of KDT501 on 
SC WAT. Multiplex analysis of gene expression revealed that 
KDT501 enhanced expression of PGC1α, PPARα, and the beige 
cell marker TMEM26 in response to cold. These findings are 
consistent with the ability of KDT501 to enhance β-adrenergic 
responses in primary brown adipocytes.
Adiponectin exists as a heterogeneous mix of multimers, 
and plasma HMW adiponectin levels are negatively correlated 
with various aspects of metabolic syndrome, including insulin 
resistance (4). Following the transcription of the adiponectin 
30  kDa monomer, considerable posttranslational processing 
and assembly of the HMW multimer occurs, leaving multiple 
possibilities for regulation. The inability of KDT501 to increase 
transcription of the adiponectin gene indicates that KDT501 
induces adiponectin secretion and multimerization posttran-
scriptionally. Multimerization of adiponectin into an HMW 
form and its secretion are complex processes regulated by ER 
stress, mitochondrial dysfunction, autophagy, and proteins 
such as ERp44, Ero1-Lα, and DsbA-L (23–26). Our studies 
demonstrating that KDT501 enhances fatty acid oxidation in 
3T3-L1 adipocytes suggest that KDT501 has beneficial effects 
on mitochondrial function. Mitochondrial function in adipose 
tissue is impaired in obesity, and recent studies suggest that 
impaired mitochondria function reduces adiponectin secre-
tion (27–29). Therefore, the ability of KDT501 to increase 
adiponectin secretion may be through its ability to enhance 
mitochondrial function, as was revealed by our in vitro assays. 
Another possible mechanism for the increase in adiponectin 
secretion induced by KDT501 could be that KDT501 sensi-
tizes adipocytes to β-adrenergic agonists, as was revealed by 
our analysis of SC WAT gene expression and in  vitro assays. 
Recent studies have demonstrated that β-adrenergic signaling 
pathways promote adiponectin secretion (22). We found that 
cold stimulates adiponectin secretion in  vivo, suggesting that 
stimulation of β-adrenergic signaling increases adiponectin 
secretion in vivo in obese subjects. Thus, the ability of KDT501 
to enhance β-adrenergic signaling may also contribute to the 
increased adiponectin secretion.
Pioglitazone has also been shown to induce adiponectin secre-
tion by posttranscriptional mechanisms (30), and PPARγ agonists 
are known for their powerful effects on increasing adiponectin 
gene expression (31). However, data from this and other studies 
FiGUrE 4 | Cold induces total and high-molecular weight (HMW) adiponectin secretion by adipose tissue explants of obese, insulin-resistant subjects. 
Adipose tissue explants obtained before and after cold treatment (30 min) before and after KDT501 treatment were incubated in Dulbecco’s modified 
Eagles’ medium (DMEM) for 4-h at 37°C. (a) Total and (B) HMW adiponectin secretion in the DMEM were measured by ELISA and are expressed as  
the concentration/g adipose/h. (C) Adiponectin gene expression was measured in the corresponding adipose tissue biopsy with the Nanostring nCounter 
system as described in the Section “Materials and Methods.” (D) Total and (E) HMW adiponectin secretion in the DMEM were measured by ELISA.  
(F) Adiponectin gene expression was measured in the corresponding adipose tissue biopsy with the Nanostring nCounter system as described in the 
Section “Materials and Methods.” Data represent the mean ± SEM (n = 9); data in all panels were analyzed by a paired, two tailed Student’s t-test 
(*P < 0.05; **P < 0.01).
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are not consistent with KDT501 directly stimulating PPARγ tran-
scriptional activity. In vitro, KDT501 has been reported to have 
pleotropic effects in adipocytes, including suppression of NFκB 
signaling (1), and, perhaps, a weak PPARγ agonist effect. However, 
in this study, we found no evidence of KDT501 PPARγ agonism 
in humans. Direct PPARγ target genes such as adiponectin, LPL, 
CD36, PNPLA2, and FABP4 were not induced by KDT501 treat-
ment (Table S2 in Supplementary Material). Suppression of inflam-
mation would also be predicted to promote adiponectin gene 
expression, but numerous inflammatory cytokine and immune 
cell markers were measured and not affected by KDT501. Thus, 
it will be important to perform additional studies to determine 
the mechanism by which KDT501 exerts changes in adiponectin 
circulating levels. Our in vitro studies suggest that an improve-
ment in mitochondrial function may be an important part of the 
mechanism.
The data in this report are consistent with the increase in 
plasma adiponectin in these research participants reported 
earlier (2). Adipose tissue explants from these same subjects 
secreted more total and HMW adiponectin after KDT501 treat-
ment. Although adiponectin levels in plasma were increased, 
our clinical study did not reveal changes in glucose metabolism 
or insulin sensitivity (2). These subjects were only treated with 
KDT501 for 28 days, and it is possible that longer treatment or 
FiGUrE 5 | Effect of KDT501 and cold on the expression of genes that 
regulate adiponectin secretion and multimerization. (a–C) Gene expression 
was measured by real-time reverse transcriptase polymerase chain reaction 
as described in the Section “Materials and Methods.” Data represent the 
mean ± SEM (n = 9); data in all panels were analyzed by a repeated 
measures analysis of variance (*P < 0.05; **P < 0.01; ***P < 0.001).  
The data in all panels were also analyzed by a paired, two tailed Student’s 
t-test of the change in gene expression by cold before and after KDT501 
treatment (ERp44: *P < 0.05).
TaBlE 4 | Real-time reverse transcriptase polymerase chain reaction primers.
Gene Forward reverse
ACTB GAG CAC AGA GCC 
TCG CCT TT
CGC GGC GAT ATC 
ATC ATC CAT
PP1A CCC ACC GTG TTC  
TTC GAC AT
GCT GTC TTT GGG  
ACC TTG TCT
PP1B AAG TCA CCG TCA  
AGG TGT ATT TT
TGC TGT TTT TGT  
AGC CAA ATC CT
TBP CCC GAA ACG CCG 
AAT ATA ATC C
AAT CAG TGC CGT  
GGT TCG TG
TUBB ACC AAC CTA CGG  
GGA TCT GAA
TTG ACT GCC AAC  
TTG CGG A
UBC 9 CTG GAA GAT GGT  
CGT ACC CTG
GGT CTT GCC AGT  
GAG TGT CT
ERp44 AGC CCA GAG ATA  
CAG GAT AAG C
GTT GCC TGA TGT  
AAT CTG CCA
ERO1L GGC TGG GGA TTC 
TTG TTT GG
AGT AAC CAC TAA  
CCT GGC AGA
DsbA-L TCT GGA AAA GAT  
CGC AAC GC
GCC CAA AGG CTC 
CGT ATC TG
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higher blood levels of KDT501 are necessary to realize the full 
beneficial effects of its ability to increase adiponectin.
Despite increasing the levels of adiponectin, which is an anti-
inflammatory adipokine, KDT501 had minimal effects on gene 
expression in the absence of a cold stimulus. One explanation 
for the lack of effect on gene expression is that the short-term 
treatment did not cause weight loss (2), change % body fat, or 
change resting energy expenditure. KDT501 treatment remod-
eled the transcriptional response of adipose tissue to cold and 
increased expression of genes involved in lipolysis and thermo-
genesis. We have recently reported that lean, healthy subjects 
respond to the same cold stimulus used in this study with a 
significant increase in expression of PGC1α and TMEM26 at 
the RNA level (13). The induction of PGC1α and TMEM26 in 
response to cold after KDT501 treatment seen here was lower 
than that measured in the lean subjects of our earlier study (13). 
Nonetheless, this indicates a beneficial effect of KDT501 on SC 
WAT, for PGC1α expression in white adipose tissue promotes 
insulin sensitivity (32). It is also important to note that this 
study was done entirely in the summer. We have previously 
documented seasonal effects on thermogenic gene expression 
in humans. Baseline expression of thermogenic genes in lean 
subjects is lower in the summer, and we saw greater changes 
in response to a cold stimulus in the summer (13). These find-
ings indicate reduced β-adrenergic signaling in humans in the 
summer, which may explain why greater changes in PGC1α 
and TMEM26 expression after KDT501 treatment were not 
seen in the present obese subjects. KDT501 robustly enhanced 
NE-stimulated cellular respiration in primary brown adipo-
cytes, suggesting a mechanism for the increase in PGC1α and 
TMEM26 expression upon cold exposure in vivo: KDT501 sen-
sitizes adipose tissue to β-adrenergic signaling. This mechanism 
may contribute to the weight loss observed in KDT501-treated 
mice, studies that were performed at room temperature, below 
thermoneutrality for mice (1).
ANGPTL4 expression was highly induced by cold after 
KDT501 treatment. Since ANGPTL4 can be induced by free fatty 
acids acting through PPARδ (33), this may be a sign of increased 
lipolysis. Interestingly, ANGPTL4 itself contributes to lipolysis 
by stimulating adipocyte cAMP levels (34, 35). Recent studies 
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in mice indicate that ANGPTL4 is induced in WAT in response 
to cold to inhibit LPL and thus favor the delivery of lipids to BAT 
(36). KDT501 appears to restore this tissue-specific regulation of 
ANGPTL4 by cold in obese subjects. PGC1α was also induced 
by cold after KDT501 treatment along with a number of other 
genes involved in lipid catabolism, including PPARα. Notably, 
UCP1 expression was not induced. This finding may be ascribed 
to the fact that cold-stimulated induction of UCP1 is blunted 
by chronic inflammation in obese subjects (13), and KDT501 
did not reduce SC WAT inflammation, as evidenced by a lack 
of change in expression of multiple inflammatory genes. It is 
also possible that the timing of the biopsies, 4 h after the 30 min 
cold stimulus, may not have been suited to capture cold-induced 
changes in UCP1 mRNA.
Taken together, the results of this initial study reveal that 
SC WAT is a physiologic target of KDT501. KDT501 acts by 
at least two mechanisms. It promotes adiponectin secretion 
by a posttranscriptional mechanism that may be related to 
its ability to improve mitochondrial function. KDT501 also 
enhances thermogenic gene expression upon cold exposure, 
a property that may be due to its ability to sensitize cultured 
adipocytes to β-adrenergic stimuli. Longer exposure to 
KDT501 may have beneficial effects on adipose tissue dysfunc-
tion implicated in conditions such as T2D, PCOS, and NASH 
in humans.
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